SubHero Banner

Trijardy XR (empagliflozin/linagliptin/metformin) – New drug approval

January 27, 2020 - Boehringer Ingelheim and Eli Lilly announced the FDA approval of Trijardy XR (empagliflozin/linagliptin/metformin), an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The empagliflozin component is also indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease.

Download PDF